DA
DARE
Dare Bioscience, Inc.
$2.34
+0.43%
$34.9M
No data for this timeframe.
Vol
Market Cap$34.9M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$1.1M
Inst. Activity2 buys / 1 sells
Reddit Sentiment67° Warm
SEC Reports6
Press Releases3
Recent Activity
May 18, 2026
fda
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
<p>Each year, an estimated six million women in the United States acquire a high-risk HPV infection
May 14, 2026
SEC
Daré Bioscience reported Q1 2026 EPS of -$0.20, a 60% beat vs the -$0.50 consensus, but this is a mechanical artifact of
PRESS-RELEASE — Impact 5/10
Apr 28, 2026
SEC
Dare Bioscience filed additional definitive proxy soliciting materials (DEFA14A) on April 28, 2026. The filing appears t
DEFA14A — Impact 2/10
Apr 22, 2026
SEC
Dare Bioscience, Inc. (DARE) filed an 8-K to disclose the availability of an updated corporate presentation on its websi
8-K — Impact 2/10
Feb 18, 2026
Insider
JOHNSON SABRINA MARTUCCI sold 10,800 shares
Chef Executive Officer @ $0.00 ($0.00)
Feb 18, 2026
Insider
JOHNSON SABRINA MARTUCCI sold 21,600 shares
Chef Executive Officer @ $0.00 ($0.00)
Jan 30, 2026
Insider
Haring-Layton MarDee sold 49,000 shares
Chief Accounting Officer @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
523,053 shares ($1.0M)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$9.67 (Dec 2025)
Current $2.34
Low $8.00
Median $9.00
High $12.00
3 analysts
$8.00
$12.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 2, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.30 ▲ +14.0% | $-0.40 — $-0.24 | 34% YoY | 3 |
| Next Q | $-0.16 ▲ +43.9% | $-0.38 — $0.10 | 43% YoY | 3 |
| Current FY | $-0.95 ▲ +21.8% | $-1.37 — $-0.57 | 21% YoY | 3 |
| Next FY | $-0.51 ▼ -187.2% | $-0.51 — $-0.51 | 46% YoY | 1 |
Latest Reports
NEUTRAL
PRESS-RELEASE
5/10
Daré Bioscience reported Q1 2026 EPS of -$0.20, a 60% beat vs the -$0.50 consensus, but this is a mechanical artifact of
May 14, 2026
NEUTRAL
DEFA14A
2/10
Dare Bioscience filed additional definitive proxy soliciting materials (DEFA14A) on April 28, 2026. The filing appears t
Apr 28, 2026
MIXED
Press
5/10
Daré Bioscience reported its 2025 financial results, highlighting a significant reduction in R&D expenses due to $16.4M
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.0M | ADD |
| TWO SIGMA INVESTMENTS, LP | $63.8K | NEW |
| RENAISSANCE TECHNOLOGIES LLC | $37.2K | TRIM |
| BANK OF AMERICA CORP | $250.00 | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 18, 2026 | JOHNSON SABRINA | A | $0.00 |
| Feb 18, 2026 | JOHNSON SABRINA | A | $0.00 |
| Jan 30, 2026 | Haring-Layton MarDee | A | $0.00 |
| Jan 30, 2026 | JOHNSON SABRINA | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
4 institutional holders with $1.1M total value (575,513 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 523,053 | $1.0M | 90.9% | ADD +32.5% |
| 2 | TWO SIGMA INVESTMENTS, LP | 33,036 | $63.8K | 5.7% | NEW |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 19,295 | $37.2K | 3.4% | TRIM -67.2% |
| 4 | BANK OF AMERICA CORP /DE/ | 129 | $250.00 | 0.0% | ADD +32.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 394,897 | 523,053 | +32.5% | $1.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 33,036 | — | $63.8K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 58,895 | 19,295 | -67.2% | $37.2K | 2025-Q4 |
| UBS Group AG | ADD | 15,008 | 22,621 | +50.7% | $47.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 99 | 131 | +32.3% | $275.00 | 2025-Q3 |
| UBS Group AG | TRIM | 22,091 | 15,008 | -32.1% | $35.9K | 2025-Q2 |
| UBS Group AG | TRIM | 32,393 | 22,091 | -31.8% | $63.8K | 2025-Q1 |
| UBS Group AG | DOUBLED | 885 | 32,393 | +3560.2% | $101.1K | 2024-Q4 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | JOHNSON SABRINA MARTUCCI | Chef Executive Officer | A | 10,800 | $0.00 | $0.00 |
| Feb 18, 2026 | JOHNSON SABRINA MARTUCCI | Chef Executive Officer | A | 21,600 | $0.00 | $0.00 |
| Jan 30, 2026 | Haring-Layton MarDee | Chief Accounting Officer | A | 49,000 | $0.00 | $0.00 |
| Jan 30, 2026 | JOHNSON SABRINA MARTUCCI | Chef Executive Officer | A | 172,000 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 4 neutral. Avg impact: 3.7/10.
NEUTRAL
PRESS-RELEASE
5/10
Daré Bioscience reported Q1 2026 EPS of -$0.20, a 60% beat vs the -$0.50 consensus, but this is a me
May 14, 2026
NEUTRAL
DEFA14A
2/10
Dare Bioscience filed additional definitive proxy soliciting materials (DEFA14A) on April 28, 2026.
Apr 28, 2026
NEUTRAL
8-K
2/10
Dare Bioscience, Inc. (DARE) filed an 8-K to disclose the availability of an updated corporate prese
Apr 22, 2026
BEARISH
8-K
5/10
Dare Bioscience completed a closing of 20,000 Investor Units in a Regulation A offering, with each u
Apr 20, 2026
NEUTRAL
8-K
2/10
Gregory W. Matz resigned as a Class II director and was immediately reappointed as a Class III direc
Apr 17, 2026
BEARISH
8-K
6/10
Dare Bioscience completed a Regulation A offering, issuing 3,470 Investor Units at $5.00 each, with
Apr 13, 2026
MIXED
5/10
Daré Bioscience reported its 2025 financial results, highlighting a significant reduction in R&D exp
Mar 26, 2026
NEUTRAL
3/10
Daré Bioscience announced a conference call to discuss its financial results for the year ended Dece
Mar 20, 2026
BULLISH
7/10
Daré Bioscience announced FDA clearance of the IND application for its planned Phase 2 clinical tria
Mar 12, 2026
Historical analyst distribution (last covering-analyst action Dec 2025): 90% buy across 10 analysts — 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$9.67 mean target (Dec 2025)
$8.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $2.34 |
| Target Low | $8.00 |
| Target Mean | $9.67 |
| Target Median | $9.00 |
| Target High | $12.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.30 | $-0.40 | $-0.24 | 34.1% | +14.0% | 1↑ 0↓ | $0.0B | 100.0% | 3 |
| Next Q 2026-09-30 |
$-0.16 | $-0.38 | $0.10 | 42.9% | +43.9% | 1↑ 0↓ | $0.0B | 80283.6% | 3 |
| Current FY 2026-12-31 |
$-0.95 | $-1.37 | $-0.57 | 21.1% | +21.8% | 2↑ 1↓ | $0.0B | 105.0% | 3 |
| Next FY 2027-12-31 |
$-0.51 | $-0.51 | $-0.51 | 46.1% | -187.2% | 1↑ 1↓ | $0.0B | 250.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.297 | |
| 7d ago | $-0.345 | +0.048 |
| 30d ago | $-0.345 | +0.048 |
| 60d ago | $-0.365 | +0.068 |
| 90d ago | $-0.365 | +0.068 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 2, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
$DARE bioscience is 30X ?
▲ 1
💬 1
⚡ 0.5
May 18, 2026
fda
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
<p>Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments</p>
May 15, 2026
short_volume
Short Volume: DARE — 55.3% short (0.4M / 0.6M)
Short: 354,493 | Exempt: 32,250 | TRF Vol: 640,799 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
<p><em>Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Comm
May 14, 2026
earnings_calendar
DARE Q1 2026 Earnings Scheduled — 2026-05-14
May 12, 2026
other
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
<p align="center"><strong>Second Positive DSMB Review Supports Continued Study Progress</strong></p>
May 11, 2026
earnings_calendar
DARE Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
short_volume
Short Volume: DARE — 56.8% short (0.5M / 0.9M)
Short: 485,904 | Exempt: 75,680 | TRF Vol: 855,224 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: DARE — 55.3% short (0.7M / 1.2M)
Short: 674,493 | Exempt: 7,226 | TRF Vol: 1,219,892 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: DARE — 62.1% short (1.4M / 2.2M)
Short: 1,369,426 | Exempt: 34,806 | TRF Vol: 2,205,592 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: DARE — 57.0% short (0.3M / 0.6M)
Short: 345,571 | Exempt: 62,743 | TRF Vol: 606,593 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: DARE — 56.1% short (2.0M / 3.5M)
Short: 1,991,981 | Exempt: 22,753 | TRF Vol: 3,549,176 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: DARE — 66.6% short (1.1M / 1.6M)
Short: 1,087,633 | Exempt: 8,391 | TRF Vol: 1,632,992 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
DARE Q4 2025 Earnings After Market Close — 2026-03-30
Mar 26, 2026
earnings
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
<p><em>Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential
Mar 23, 2026
other
On National Viagra Day, Women Finally Claim Their Turn:
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her <pre>DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual